Aurintricarboxylic acid - CAS:4431-00-9

您当前的位置：

Aurintricarboxylic acid (Synonyms:金精三羧酸)

目录号 : KM2877 CAS No. : 4431-00-9

Data Sheet 产品使用指南

Aurintricarboxylic acid 是高效的，αβ-亚甲基-ATP 敏感选择性 P2X1Rs 和 P2X3Rs 变构拮抗剂，对 rP2X1R 和 rP2X3R 作用的 IC₅₀ 值分别为 8.6 nM 和 72.9 nM。Aurintricarboxylic acid 是一种有效的抗流感剂，通过直接抑制神经氨酸酶 (neuraminidase) 作用。Aurintricarboxylic acid 也是拓扑异构酶 II 和凋亡抑制剂。Aurintricarboxylic acid 是选择性的 TWEAK-Fn14 信号通路抑制剂。Aurintricarboxylic acid 也是一种胱硫醚-γ-裂解酶 (CSE) 抑制剂，其 IC₅₀ 值为 0.6 μM。Aurintricarboxylic acid 是能够调节 miRNA 功能的 miRNA 调节剂。

规格	价格	是否有货
100mg		In-stock
200mg	询价	In-stock
500mg	询价	In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Ginkgolic Acid (C13:0) In-stock
Lalistat 1 In-stock
Ciprofloxacin hydrochloride monohydrate In-stock
Cyclosporin C In-stock
Isobavachromene In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

Aurintricarboxylic acid is a nanomolar-potency, allosteric antagonist with selectivity towards αβ-methylene-ATP-sensitive P2X1Rs and P2X3Rs, with IC₅₀s of 8.6 nM and 72.9 nM for rP2X1R and rP2X3R, respectively. Aurintricarboxylic acid is a potent anti-influenza agent by directly inhibiting the neuraminidase. Aurintricarboxylic acid is an inhibitor of topoisomerase II and apoptosis. Aurintricarboxylic acid is a selective inhibitor of the TWEAK-Fn14 signaling pathway. Aurintricarboxylic acid also acts as a cystathionine-lyase (CSE) inhibitor with an IC₅₀ of 0.6 μM. Aurintricarboxylic acid is a modifier of miRNAs that regulate miRNA function, with an IC₅₀ of 0.47 µM.

体外研究

Aurintricarboxylic acid weakly inhibits P2X2/3Rs, P2X2Rs, P2X4Rs or P2X7Rs.
Aurintricarboxylic acid inhibits ATP-induced currents in a concentration dependent manner.
Aurintricarboxylic acid can inhibit the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) and vaccinia virus.
Aurintricarboxylic acid inhibits replication of influenza A and B viruses by inhibition of neuraminidase activities.
Aurintricarboxylic acid inhibits TWEAK-Fn14-mediated NF-κB activation.
Aurintricarboxylic acid (10 μM; 0.5-2 hours) suppresses TWEAK-Fn14-mediated NF-κB, Akt, and Src phosphorylation in GBM cells.
Aurintricarboxylic acid represses TWEAK-stimulated glioma cell migration and invasion without causing cell cytotoxicity.
Aurintricarboxylic acid (Compound 8) cannot regulate loading of endogenous let-7 onto AGO2 inside cultured cells, whereas can inhibit RISC loading of exogenous siRNA.

Western Blot Analysis

Cell Line:	T98G, A172, GBM44 glioma cells
Concentration:	10 μM
Incubation Time:	0.5 hour, 1 hour, 2 hours
Result:	Abrogated TWEAK activation of downstream signals including phosphorylation of the NF-κB family member p65, Akt, and Src in all three GBM cell lines.

分子式

C₂₂H₁₄O₉

分子量

422.34

CAS号

4431-00-9

中文名称

金精三羧酸

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 125 mg/mL (295.97 mM; Need ultrasonic)

H₂O : < 0.1 mg/mL (ultrasonic) (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3678 mL	11.8388 mL	23.6776 mL
5 mM	0.4736 mL	2.3678 mL	4.7355 mL
10 mM	0.2368 mL	1.1839 mL	2.3678 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (4.92 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.92 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (4.92 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.92 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。